

RHINOMED TO PRESENT AT 2015 BIO

KEY HIGHLIGHTS:

- **Rhinomed accepted as a speaker at Global 2015 BIO Convention, Philadelphia, USA June 15-18**
- **Company to showcase sleep and drug delivery platform advances**
- **Continuing on from successful recent distribution deals; reflects major push into global sleep and drug delivery markets**

18th May, 2015. Melbourne, Australia. Rhinomed Ltd (ASX:RNO) is pleased to announce that it has been accepted as a presenter at 2015 BIO, the world's leading biotech convention to be held in Philadelphia, June 15-18th.

BIO is one of the premier global biotech conferences. It is attended by over 15,000 biotech and pharma leaders and provides an important opportunity for the company to expose its patented nasal platform technology to a broader range of potential partners and distributors.

With clear progress being made within its Sport and Sleep business units, the imminent start of the sleep apnoea trial featuring its new INPEAP technology, and progress in the drug delivery program, the business is receiving strong interest globally.

“BIO is a great opportunity to extend the conversations we are already having with a range of parties. It also provides a great opportunity to introduce our platform to a much broader set of the world's leading biotech and pharma companies,” commented CEO Michael Johnson.

“Rhinomed’s internal nasal platform is rapidly gaining acceptance with thousands of users in both sport and sleep. With this growing level of acceptance, the platform provides a highly attractive, patented and de-risked delivery platform for sleep and drug development companies and pharma,” Johnson said.

The company will be travelling and exhibiting as part of the Victorian Government’s delegation to 2015 BIO.

RHINOMED

MAKE EVERY BREATH COUNT

Media Enquiries

Michael Johnson, CEO & Director

+61 (03) 8416 0900

mjohnson@rhinomed.global

Follow us on

Twitter @rhinomedceo and @mutesnoring and @theturbinecom

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to

www.rhinomed.global

About the Mute™

Mute™ is a unique nasal respiratory technology that has been found to reduce the volume and frequency of snoring in 75% of users. Mute is easy to use, drug free and fits discreetly inside the nose. Designed to give snoring the silent treatment and made from ultra-soft polymers, Mute gently expands each nostril to increase the volume of air in each breath. By doing so, Mute encourages nasal breathing and reduces the need to open the mouth during sleep, factors critical to a reduction in snoring and better sleep quality. For more information or to purchase online, visit www.mutesnoring.com

About the Turbine™

Turbine™ is a revolutionary respiratory technology designed specifically for the sport market. Turbine delivers an average increase of 38% more airflow through the nasal passages and has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training. You can purchase a Turbine by visiting www.theturbine.com